Recent Advances in Immunohistochemical and Molecular Profiling for Differential Diagnosis Between Giant Cell-rich Lesions and Tenosynovial Giant Cell Tumors

Overview

Journal Front Oncol

Date 2025 Jan 24

PMID 39850815

Authors

Jiro Ichikawa

Tomonori Kawasaki

Satoshi Ochiai

Masanori Wako

Tetsuo Hagino

Kaoru Aoki

Kojiro Onohara

Affiliations

Soon will be listed here.

References

Fritchie K, Torres-Mora J, Inwards C, Thway K, Vaiyapuri S, Jackson R . Xanthogranulomatous epithelial tumor: report of 6 cases of a novel, potentially deceptive lesion with a predilection for young women. Mod Pathol. 2020; 33(10):1889-1895. DOI: 10.1038/s41379-020-0562-8. View

Sugita S, Takenami T, Kido T, Aoyama T, Hosaka M, Segawa K . Diagnostic utility of CSF1 immunohistochemistry in tenosynovial giant cell tumor for differentiating from giant cell-rich tumors and tumor-like lesions of bone and soft tissue. Diagn Pathol. 2022; 17(1):88. PMC: 9623913. DOI: 10.1186/s13000-022-01266-9. View

Hartmann W, Harder D, Baumhoer D . Giant Cell-Rich Tumors of Bone. Surg Pathol Clin. 2021; 14(4):695-706. DOI: 10.1016/j.path.2021.06.010. View

Wang Z, Wang X, Zhang S . A Case Report of Diffuse-type Tenosynovial Giant Cell Tumor as a Calcaneus Mass: A Diagnostic Challenge. Curr Med Imaging. 2024; . DOI: 10.2174/0115734056286012240111093147. View

Amary F, Berisha F, Ye H, Gupta M, Gutteridge A, Baumhoer D . H3F3A (Histone 3.3) G34W Immunohistochemistry: A Reliable Marker Defining Benign and Malignant Giant Cell Tumor of Bone. Am J Surg Pathol. 2017; 41(8):1059-1068. PMC: 5510691. DOI: 10.1097/PAS.0000000000000859. View

Shooshtarizadeh T, Rahimi M, Movahedinia S . P63 expression as a biomarker discriminating giant cell tumor of bone from other giant cell-rich bone lesions. Pathol Res Pract. 2016; 212(10):876-879. DOI: 10.1016/j.prp.2016.07.007. View

Gelderblom H, Bhadri V, Stacchiotti S, Bauer S, Wagner A, van de Sande M . Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2024; 403(10445):2709-2719. PMC: 11740396. DOI: 10.1016/S0140-6736(24)00885-7. View

Boland J, Folpe A, Hornick J, Grogg K . Clusterin is expressed in normal synoviocytes and in tenosynovial giant cell tumors of localized and diffuse types: diagnostic and histogenetic implications. Am J Surg Pathol. 2009; 33(8):1225-9. DOI: 10.1097/PAS.0b013e3181a6d86f. View

Rekhi B, Dave V . Giant cell tumor of bone: An update, including spectrum of pathological features, pathogenesis, molecular profile and the differential diagnoses. Histol Histopathol. 2022; 38(2):139-153. DOI: 10.14670/HH-18-486. View

10.

Pizem J, Sekoranja D, Matjasic A, Zupan A, Bostjancic E, Limpel Novak K . The role of molecular diagnostics in aneurysmal and simple bone cysts - a prospective analysis of 19 lesions. Virchows Arch. 2021; 479(4):795-802. DOI: 10.1007/s00428-021-03130-5. View

11.

Crim J, Dyroff S, Stensby J, Evenski A, Layfield L . Limited usefulness of classic MR findings in the diagnosis of tenosynovial giant cell tumor. Skeletal Radiol. 2021; 50(8):1585-1591. DOI: 10.1007/s00256-020-03694-4. View

12.

Guimaraes L, Gomes I, Pereira T, de Andrade B, Romanach M, de Lacerda J . KRAS mutations in brown tumor of the jaws in hyperparathyroidism. J Oral Pathol Med. 2020; 49(8):796-802. DOI: 10.1111/jop.13048. View

13.

Legrand M, Jourdan M, De Pinieux G . Histopathogenesis of bone- and soft-tissue tumor spectrum with USP6 gene rearrangement: multiple partners involved in the tissue repair process. Histol Histopathol. 2022; 38(3):247-260. DOI: 10.14670/HH-18-532. View

14.

Luke J, von Baer A, Schreiber J, Lubbehusen C, Breining T, Mellert K . H3F3A mutation in giant cell tumour of the bone is detected by immunohistochemistry using a monoclonal antibody against the G34W mutated site of the histone H3.3 variant. Histopathology. 2017; 71(1):125-133. DOI: 10.1111/his.13190. View

15.

Behjati S, Tarpey P, Presneau N, Scheipl S, Pillay N, Van Loo P . Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nat Genet. 2013; 45(12):1479-82. PMC: 3839851. DOI: 10.1038/ng.2814. View